Seres Therapeutics Announces FDA Clearance of IND for Investigational Microbiome Therapeutic for the Prevention of Antibiotic-Resistant Bacterial Infections and GvHD
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announces the U.S. Food and Drug Administration (FDA) has indicated studies for SER-155 may proceed under an Investigational New Drug (IND) application. SER-155 is an […]
